



# Kent Academic Repository

Ogden, Henry B., Fallowfield, Joanne L., Child, Robert B., Davison, Glen, Fleming, Simon C., Delves, Simon K., Millyard, Alison, Westwood, Caroline S. and Layden, Joseph D. (2022) *No protective benefits of low dose acute L-glutamine supplementation on small intestinal permeability, epithelial injury and bacterial translocation biomarkers in response to subclinical exertional-heat stress: A Randomized cross-over trial.* Temperature . ISSN 2332-8940.

## Downloaded from

<https://kar.kent.ac.uk/95024/> The University of Kent's Academic Repository KAR

## The version of record is available from

<https://doi.org/10.1080/23328940.2021.2015227>

## This document version

Author's Accepted Manuscript

## DOI for this version

## Licence for this version

UNSPECIFIED

## Additional information

## Versions of research works

### Versions of Record

If this version is the version of record, it is the same as the published version available on the publisher's web site. Cite as the published version.

### Author Accepted Manuscripts

If this document is identified as the Author Accepted Manuscript it is the version after peer review but before type setting, copy editing or publisher branding. Cite as Surname, Initial. (Year) 'Title of article'. To be published in *Title of Journal* , Volume and issue numbers [peer-reviewed accepted version]. Available at: DOI or URL (Accessed: date).

## Enquiries

If you have questions about this document contact [ResearchSupport@kent.ac.uk](mailto:ResearchSupport@kent.ac.uk). Please include the URL of the record in KAR. If you believe that your, or a third party's rights have been compromised through this document please see our [Take Down policy](https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies) (available from <https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies>).

1 **TITLE:**

2 No benefit of low dose acute L-glutamine supplementation on small intestinal permeability,  
3 epithelial injury or bacterial translocation biomarkers in response to subclinical exertional-  
4 heat stress: A randomised cross-over trial

5 **AUTHORS:**

6 Henry B. Ogden <sup>1</sup>., Joanne L. Fallowfield <sup>2</sup>., Robert B. Child <sup>3</sup>., Glen Davison <sup>4</sup>., Simon C.  
7 Fleming <sup>5</sup>., Simon K. Delves <sup>2</sup>., Alison Millyard <sup>1</sup>., Caroline S. Westwood <sup>1</sup>. and Joseph D.  
8 Layden <sup>1</sup>

9

10 **AUTHOR AFFILIATION:**

11 <sup>1</sup> School of Sport, Health and Wellbeing, Plymouth MARJON University, Plymouth, United  
12 Kingdom

13 <sup>2</sup> Institute of Naval Medicine, Alverstoke, United Kingdom

14 <sup>3</sup> School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom

15 <sup>4</sup> Endurance Research Group, School of Sport and Exercise Sciences, University of Kent,  
16 Chatham Maritime, United Kingdom

17 <sup>5</sup> Royal Cornwall NHS trust, Truro, United Kingdom

18

19 **RUNNING TITLE:**

20 No Protective Effect of Glutamine on Gastrointestinal Barrier Integrity in Response to  
21 Exertional-Heat Stress

22

23 **KEYWORDS:**

24 Gut, Exercise, Endotoxin, I-FABP, Microbiota, Heat Stroke

25

26 **TOTAL PAGES/WORDS:**

27 22/5828 (Main Body)

28

29 **TOTAL REFERENCES:**

30 72

31

32 **CORRESPONDING AUTHOR:**

33 Henry B. Ogden

34 Plymouth MARJON University

35 Faculty of Sport, Health and Wellbeing,

36 Derriford Rd, Plymouth, PL6 8BH, United Kingdom

37 Telephone: 0791 454 0094

38 Email: ogden.h@pgr.marjon.ac.uk

39

40 **SUBJECT AREA:**

41 Occupational and Environmental Exercise Physiology

42

43 **COMPETING INTERESTS:**

44 The authors declare there are no competing interests

45

46

47 **NEW AND NOTEWORTHY:**

48 This study aimed to assess the influence of acute low-dose glutamine supplementation on  
49 small intestinal permeability, injury and bacterial translocation biomarkers in response to  
50 exertional-heat stress. Whilst the glutamine supplement was well-tolerated, gastrointestinal  
51 injury, permeability or bacterial translocation was not improved, in comparison to a non-  
52 calorific placebo.

53

54 **ABSTRACT**

55 **INTRODUCTION:** Exertional-heat stress disrupts gastrointestinal permeability, and through  
56 subsequent bacterial translocation, can result in potentially fatal exertional-heat stroke.  
57 Glutamine supplementation is a potential countermeasure, although previously validated  
58 doses are not universally well-tolerated. **METHODS:** Ten males completed two 80-minute  
59 subclinical exertional-heat stress tests (EHST) following either glutamine (0.3 g·kg·FFM<sup>-1</sup>) or  
60 placebo supplementation. Small intestinal permeability was assessed using the  
61 lactulose/rhamnose dual-sugar absorption test and small intestinal epithelial injury using  
62 Intestinal Fatty-Acid Binding Protein (I-FABP). Bacterial translocation was assessed using total  
63 16S bacterial DNA and *Bacteroides*/total 16S DNA ratio. **RESULTS:** The glutamine bolus was  
64 well tolerated, with no participants reporting symptoms of gastrointestinal intolerance. Small  
65 intestinal permeability was not influenced by glutamine supplementation ( $p = 0.06$ ), though  
66 a medium effect size favouring the placebo trial was observed ( $d = 0.73$ ). Both small intestinal  
67 epithelial injury ( $p < 0.01$ ) and *Bacteroides*/total 16S DNA ( $p = 0.04$ ) increased following  
68 exertional-heat stress, but were uninfluenced by glutamine supplementation. **CONCLUSION:**  
69 Acute low-dose oral glutamine supplementation does not protect gastrointestinal injury,  
70 permeability, or bacterial translocation in response to subclinical exertional-heat stress.

71 **DECLARATIONS:**

72 *Funding:* The authors did not receive support from any organization for the submitted work.

73 *Conflicts of Interest:* No author has any conflicts of interest to declare.

74

75 *Data Availability:* The datasets generated during and/or analysed during the current study are  
76 available from the corresponding author on reasonable request.

77

78 *Author Contributions:* H.B.O, J.L.F, R.B.C, S.K.D and J.D.L conceived and designed research.  
79 H.B.O, G.D, S.C.F and A.M. conducted experiments. G.D and S.C.F contributed new reagents  
80 or analytical tools. H.B.O and J.D.L. analysed data. H.B.O wrote the manuscript. All authors  
81 read and approved the manuscript.

82

83 *Ethics Approval:* The study protocol was approved by Plymouth MARJON University Research  
84 Ethics Committee (Approval Code: EP097) and was conducted in accordance with the  
85 principles outlined in the 1964 Declaration of Helsinki and its later amendments

86

87 *Consent to Participate:* Informed consent was obtained from all individual participants  
88 included in the study.

89

90 *Consent for Publications:* Patients signed informed consent regarding publishing their  
91 anonymised data.

92

93 **ABBREVIATIONS**

94	ANOVA	Analysis of variance
95	CV	Coefficient of Variation
96	EDTA	Ethylenediaminetetraacetic acid
97	EHST	Exertional Heat Stress Test
98	ELISA	Enzyme Linked Immunosorbent Assay
99	FFM	Fat Free Mass
100	HPLC	High Performance Liquid Chromatography
101	I-FABP	Intestinal Fatty-Acid Binding Protein
102	L/R	Lactulose-to-Rhamnose
103	mVAS	Modified Visual Analogue Scale
104	qPCR	Quantitative Polymerase Chain Reaction
105	RH	Relative Humidity
106	RPE	Rate of Perceived Exertion
107	SD	Standard Deviation
108	SEM	Sensor Electronics Module
109	T <sub>core</sub>	Core Body Temperature
110	T <sub>body</sub>	Mean Body Temperature
111	T <sub>skin</sub>	Mean Skin Temperature
112	$\dot{V}O_{2max}$	Maximal Oxygen Uptake
113		
114		

115 **INTRODUCTION**

116 Exertional heat stroke is the most severe disorder along the continuum of heat-related  
117 illnesses (Leon and Bouchama, 2011). It is a condition that sporadically affects young  
118 individuals engaged in arduous physical activity, including athletes, military personnel, and  
119 labourers. Whilst direct mortality from exertional heat stroke is largely preventable with  
120 provision of rapid (< 1 hour) whole-body cooling (DeMartini et al., 2015), many casualties  
121 experience lifelong health complications because of residual organ damage (Wallace et al.,  
122 2007). The pathophysiology of EHS has been hypothesised to be at least partially attributable  
123 to a systemic inflammatory response triggered by the translocation of pathogenic microbes  
124 from the gastrointestinal lumen into the systemic circulation (Lim, 2018; Fung et al., 2021;  
125 Walter et al., 2021). Consequently, contemporary research has focussed on evaluating the  
126 efficacy of nutritional countermeasures to support intestinal permeability, epithelial injury,  
127 and bacterial translocation in response to exertional-heat stress (Costa et al., 2020; Ogden et  
128 al., 2020a).

129 L-glutamine is the most abundant free amino acid in the human body (Newsholme et  
130 al., 2003). It is classified as a conditionally essential nutrient, given it is the preferential energy  
131 source of rapidly proliferating cells (e.g. leukocytes), but becomes depleted during severe  
132 catabolism (Lacey and Wilmore, 1990). In addition to being an important energy substrate, L-  
133 glutamine performs various other essential physiological roles, including: nitrogen  
134 transportation; gluconeogenesis; acid-base regulation; and the biosynthesis of glutathione,  
135 nitric oxide and heat shock proteins (Gleeson, 2008). Based on these functions, L-glutamine  
136 supplementation has previously been demonstrated to protect small intestinal permeability  
137 and epithelial injury in response to exertional-heat stress (Zuhl et al., 2014, 2015; Pugh et al.,

138 2017). For example, Zuhl et al. (2014) found one week of daily L-glutamine supplementation  
139 (0.9 g·kg·fat free mass<sup>-1</sup> [FFM]) attenuated the ~3-fold rise in small intestinal permeability  
140 following one-hour of running at 70% VO<sub>2max</sub> in the heat (30°C). These findings were  
141 subsequently replicated with a single acute glutamine bolus (0.9 g·kg·FFM<sup>-1</sup>) ingested two  
142 hours prior to exertional-heat stress (Zuhl et al., 2015; Pugh et al., 2017).

143           Unfortunately, high-dose oral glutamine ingestion ( $\geq 0.75$  g·kg·FFM<sup>-1</sup>) appears to have  
144 limited ecological validity, given reports of gastrointestinal symptoms such as bloating,  
145 nausea and vomiting in some study participants (Ward et al., 2003; Pugh et al., 2017; Ogden  
146 et al., 2020d). One solution to overcome this issue is to reduce the glutamine dose to *circa*  
147 0.2-0.3 g·kg<sup>-1</sup> where adverse gastrointestinal symptoms become negligible (Ziegler et al.,  
148 1990; Ogden et al., 2020d). Whilst the importance of regular macronutrient ingestion (e.g. 30  
149 – 60 g·hour<sup>-1</sup> of liquid carbohydrate) has been widely-advocated as a nutritional  
150 countermeasure to protect small intestinal permeability during exertional-heat stress  
151 (Lambert et al., 2001; Snipe et al., 2017; Flood et al., 2020; Jonvik et al., 2020), it is not a  
152 universally effective strategy (Lambert et al., 2001; Sessions et al., 2016; Pugh et al., 2020),  
153 whilst in favourable studies the protection afforded on the gastrointestinal barrier had little  
154 influence on downstream bacterial translocation (Snipe et al., 2017; Jonvik et al., 2020).  
155 Furthermore, during short-notice occupational deployments where exertional-heat stroke is  
156 commonplace, such as military operations, wildland fire fighting and emergency first  
157 responses, consideration must be given to the logistical constraints associated with any  
158 proposed nutritional intervention. This includes the ability to carry the required food/drink  
159 on person, acceptable gastrointestinal tolerance and affordability (Ogden et al., 2020a).  
160 Based on these considerations, low acute dose glutamine supplementation (0.2-0.3 g·kg<sup>-1</sup>)

161 would appear to have better practicality than other previously researched nutritional  
162 countermeasures (e.g. chronic bovine colostrum or probiotic supplementation). The efficacy  
163 of low dose glutamine supplementation (12 grams) has previously been demonstrated to  
164 protect small intestinal permeability when ingested 30 minutes prior to gastrointestinal  
165 disturbance induced by a non-steroidal anti-inflammatory pharmaceutical (Hond et al., 1999).

166 The aim of the present study was to assess the influence of acute low-dose (0.3  
167 g·kg·FFM<sup>-1</sup>) oral glutamine supplementation on small intestinal permeability, epithelial injury  
168 and bacterial translocation in response to exertional-heat stress. The primary hypothesis was  
169 that glutamine supplementation would protect small intestinal permeability, epithelial injury  
170 and reduce bacterial translocation in response to exertional-heat stress.

## 171 **METHODS**

172 Twelve healthy males volunteered to participate in the study. Two participants  
173 withdrew before study completion due to injury independent of the study; therefore, data is  
174 reported for the remaining ten completing participants (Table 1). All participants were non-  
175 smokers, who habitually exercised (>4 h·week<sup>-1</sup>), were non-endurance trained ( $VO_{2max} \leq 55$   
176 ml·kg<sup>-1</sup>·min<sup>-1</sup>) and unacclimated to hot environments. This demographic could be considered  
177 broadly representative of UK military personnel in ground combat roles (Fallowfield et al.,  
178 2019). A general medical questionnaire was used to screen for previous histories of  
179 gastrointestinal, cardiorespiratory and metabolic illnesses. No participant self-reported taking  
180 pharmacological medications or having suffered from an acute respiratory or gastrointestinal  
181 illness within 14 days prior to data collection. Informed consent was obtained for each  
182 participant following a full written and oral explanation of the experimental procedures. The  
183 study protocol was approved by Plymouth MARJON University Research Ethics Committee

184 (Approval Code: EP097) and was conducted in accordance with the principles outlined in the  
185 1964 Declaration of Helsinki and its later amendments.

186 [Table 1 – Insert Here]

187 Participants visited the laboratory on three occasions. Baseline anthropometrics and  
188 maximal oxygen uptake ( $\dot{V}O_{2\max}$ ) were assessed during the first visit. The two subsequent  
189 visits were main experimental trials, where participants were supplemented with either  
190 glutamine or placebo in a randomised, counterbalanced, double-blind cross-over design. Trial  
191 order was determined by a computer-generated random number generator  
192 ([www.randomizer.org](http://www.randomizer.org)) and participants assigned *a priori* by an individual independent of  
193 primary data collection. Study trials were separated by 7-14 days to minimise the influence of  
194 prior exertional-heat stress on thermoregulatory (Barnett and Maughan, 1993) and  
195 gastrointestinal biomarker (Ogden et al., 2020b) responses.

196 During both main experimental trials, participants completed an intermittent  
197 exertional-heat stress test (EHST), consisting of two bouts of 40 minutes fixed-intensity  
198 treadmill walking ( $6 \text{ km}\cdot\text{h}^{-1}$  and 7% gradient) in the heat ( $35^{\circ}\text{C}$  and 30% relative humidity; RH).  
199 The exercise bouts were separated by 20-minutes seated recovery. This protocol was  
200 designed in line with military work/rest schedule guidance, consistent across different  
201 militaries worldwide (Spitz et al., 2012). In comparison with previous research from our  
202 laboratory that applied this study design (Ogden et al., 2020b, 2020c), forearm cold water  
203 immersion and fluid replacement interventions were removed, with the aim to enhance  
204 gastrointestinal barrier insult (Costa et al., 2019). Data collection coincided with non-summer  
205 months in Plymouth, United Kingdom, where daily mean ambient temperature at a local

206 meteorological station (Camborne, United Kingdom; latitude: 50.218 ° N) remained below  
207 20°C (Met Office, 2020). A schematic illustration of the protocol is shown in Figure 1.

208 [Figure 1 – Insert Here]

209 Dietary supplements (e.g. probiotics) and prolonged thermal exposures (e.g. saunas)  
210 were prohibited from 14 days before until the end of data collection. Alcohol, caffeine,  
211 strenuous physical activity, non-steroidal anti-inflammatory drugs (e.g. ibuprofen) and spicy  
212 foods were all abstained for 48 hours before main experimental visits. Dietary macronutrient  
213 composition in the days prior to trial visits was not tightly controlled to minimise participant  
214 burden, although participants were requested to match their habitual diet as close as possible  
215 between repeated visits. Participants adhered to a  $\geq 10$  hour overnight fast and consumed  
216 500 ml of plain water two hours prior to main experimental visits. Conformity with all pre-  
217 trial controls was self-attested in writing upon laboratory arrival using a questionnaire.  
218 Participants remained fasted throughout main experimental trials (Edinburgh et al., 2018).

219 Glutamine supplementation consisted of  $0.3 \text{ g}\cdot\text{kg}^{-1}$  fat free mass of glutamine  
220 crystalline powder (L-glutamine Elite, Myprotein, Northwich, UK; Batch Number:  
221 W920126073), which was freshly suspended in 500 ml of water/lemon flavour cordial (4:1  
222 ratio; Fruit Squash – no added sugar, Robinsons, UK). Participants ingested the entire fluid  
223 bolus within a 5-10 minute period, finishing one hour before commencing the EHST. Placebo  
224 supplements were taste and consistency matched, comprised of the identical water/lemon  
225 flavour sugar-free cordial alone. Both supplements were administered in an opaque bottle to  
226 match visual appearance. Supplements were prepared by an individual independent of the  
227 study.

228 Height was measured barefoot using a stadiometer to the nearest 0.1 cm (HM-200,  
229 Marsden, Rotherham, UK). Body mass was measured on an electronic scale to the nearest  
230 0.05 kg (MC 180 MA, Tanita, Tokyo, Japan). Skinfold thicknesses were taken in duplicate  
231 (coefficient of variation [CV] = 2.2%) by the same researcher at the bicep, tricep, subscapular  
232 and suprailiac using skinfold callipers to the nearest 0.1 cm (Harpندن, Holtain Ltd, Crymych,  
233 UK). Predictions of body density were calculated using age- and sex-relevant equations  
234 (Durnin and Womersley, 1974).

235 Maximal oxygen uptake ( $\dot{V}O_{2max}$ ) was determined using an incremental treadmill test  
236 (Desmo HP, Woodway GmbH, Weil am Rhein, Germany) to volitional exhaustion described in  
237 detail elsewhere (Ogden et al., 2020b).

238 The EHST commenced in the morning (08:30  $\pm$  1 hour) to standardise the influence of  
239 circadian variation (Gaskell et al., 2020b). Upon laboratory arrival, participants provided a  
240 mid-flow urine sample to assess hydration status. Duplicate urine osmolality measurements  
241 were undertaken via freeze-point depression (Osmomat 3000, Gonotec, Berlin, Germany; CV  
242 = 0.5%) and urine specific gravity via a digital refractometer (3741 Pen-Urine S.G, Atago Co.  
243 Ltd, Tokyo, Japan; CV = <0.1%). Participants measured their own nude body mass (180 MA,  
244 Tanita MC, Tokyo, Japan), before self-inserting a single use rectal thermistor ( $T_{core}$ ; Phillips  
245 21090A, Guildford, UK) 12 cm beyond the anal sphincter. A heart rate monitor was positioned  
246 around participants' chest (EQ02, Equivital™, Cambridge UK) and was measured using a  
247 Sensor Electronics Module (SEM) unit (EQ02, Equivital™, Cambridge UK). Participant dress-  
248 state was standardised using summer military clothing (i.e. jacket [neck zipped, sleeves  
249 extended], trousers, boxer briefs, socks, trainers). The environmental chamber was regulated

250 at  $\sim 35^{\circ}\text{C}$  (glutamine:  $35.3 \pm 0.3^{\circ}\text{C}$ ; placebo:  $35.3 \pm 0.2^{\circ}\text{C}$ ;  $p = 0.15$ ) and  $\sim 30\%$  RH (glutamine:  $31$   
251  $\pm 1\%$ ; placebo:  $30 \pm 1\%$ ;  $p = 0.44$ ). On entry to the chamber, skin thermistors (EUS-UU-VL3-O,  
252 Grant Instruments, Cambridge, UK) were affixed to the participant using one layer (5 x 5 cm)  
253 of cotton tape (KT Tape<sup>®</sup>, KT Health, UT, USA); and mean skin temperature ( $T_{\text{skin}}$ ) was  
254 calculated using standard equations (Ramanathan, 1964).

255 Throughout the EHST,  $T_{\text{core}}$  and  $T_{\text{skin}}$  were continuously recorded using a temperature  
256 logger (Squirrel SQ2010, Grant Instruments, Cambridge, UK) and heat rate was recorded using  
257 a Sensor Electronics Module (SEM) unit (EQ02, Equivital<sup>™</sup>, Cambridge UK). Mean whole body  
258 temperature ( $T_{\text{body}}$ ) was calculated from simultaneous  $T_{\text{core}}$  and  $T_{\text{skin}}$  measurements (Jay and  
259 Kenny, 2007). All data, including rating of perceived exertion (RPE; Borg et al., 1970), thermal  
260 sensation (Toner et al., 1986) and gastrointestinal symptoms (Gaskell et al., 2019) were  
261 reported at 20-minute intervals. For each perceptual measure, participants were given  
262 standardised instructions to ensure understanding of anchoring the top and bottom ratings  
263 to previous perceptions or experiences during exertional-heat stress. Gastrointestinal  
264 symptoms are presented as the incidence (%) and accumulated severity of symptoms,  
265 grouped following previous guidance (Gaskell et al., 2019). Absolute sweat losses were  
266 calculated from the change in dry nude body mass from pre-to-post EHST.

267 Venous blood samples (12 ml) were drawn immediately pre and post the EHST. At rest,  
268 participants stood upright for a minimum of 20 minutes before collection to allow capillary  
269 filtration pressure to stabilise (Shirreffs and Maughan, 1994). Blood was drawn from a  
270 forearm antecubital vein under minimal stasis (<30 seconds) and following sterilisation with  
271 an 80% isopropyl alcohol wipe. Samples were collected proportionally into serum-separator  
272 (SST II) and  $\text{K}_2$  EDTA tubes (Becton Dickinson and Company, Plymouth, UK). The SST II tube

273 was allowed to clot for 30-40 minutes at room temperature. A 0.5ml aliquot of K<sub>2</sub>EDTA blood  
274 was removed for immediate haematological analysis. Samples were centrifuged at 1300g for  
275 15 minutes at 4°C to separate serum and plasma. Aliquots were transferred into microtubes  
276 without disrupting cells and then frozen at -80°C until analyses. All blood handling was  
277 performed with manufacturer certified sterile (pyrogen, DNA free) pipette tips and  
278 microtubes.

279 Haemoglobin was measured using a portable photometric analyser (Hemocue® Hb  
280 201+, EFK Diagnostics, Madeburg, Germany; Duplicate; CV = 0.4%) and haematocrit using the  
281 microcapillary technique following centrifugation at 14,000g for 4 minutes at room  
282 temperature (Haematospin 1400, Hawksley and Sons Ltd, Lancing, England; CV = 0.6%).  
283 Changes in plasma volume was estimated using standard equations (Dill and Costill, 1974).  
284 Post-exercise analyte concentrations were left uncorrected for acute plasma volume shifts,  
285 given the similarity of responses between trials and the low molecular weights of quantified  
286 analytes. Plasma osmolality was examined in duplicate (CV = <0.1%) using freeze-point  
287 depression (Osmomat 3000, Gonotec, Berlin, Germany).

288 Participants orally ingested a standard sugar probe solution containing 5 g Lactulose  
289 (Lactulose Oral Solution, Sandoz, Holzkirchen, Germany) and 2 g L-Rhamnose (L-rhamnose FG,  
290 99% pure, Sigma Aldrich, Missouri, USA) dissolved within 50 ml of plain water (osmolality =  
291 ~750 mOsm·kg<sup>-1</sup>) ten minutes into the EHST. Probe concentrations were determined in  
292 duplicate serum samples collected 90 minutes following probe ingestion (i.e. post-EHST)  
293 following a previously described high performance liquid chromatography (HPLC) protocol  
294 (Fleming et al., 1996). The recovery of both sugars was determined per litre serum (mg·l<sup>-1</sup>),  
295 where the lactulose/L-rhamnose (L/R) was then corrected relative (%) to the concentration of

296 sugar consumed. The limit of detection was 0.1 mg·l<sup>-1</sup>. The combined L/R coefficient of  
297 variation was 8.7%.

298 I-FABP (1:4 plasma dilution) was measured in duplicate plasma samples pre and  
299 immediately post EHST using a solid-phase sandwich ELISA (DY3078, DuoSet, R&D systems,  
300 Minneapolis, USA) following manufacturer instructions. The intra-assay coefficient of  
301 variation was 2.0%.

302 Bacterial DNA was measured in duplicate plasma samples collected pre and  
303 immediately post EHST using a quantitative real-time polymerase chain reaction assay (qPCR)  
304 on a LightCycler 96 instrument (LightCycler 96, Roche, Basel, Switzerland). DNA was isolated  
305 from plasma using a Quick-DNA Mini Prep Plus kit (D4068, Zymo Research, Irvine, CA, USA)  
306 following manufacturer's instructions. The elution buffer was heated to 65°C before use. Total  
307 16S bacterial DNA was quantified according to March et al. (2019) using a universal library  
308 probe (Roche, Basel, Switzerland), with standards (E2006-2, Zymo Research, Irvine, CA, USA)  
309 and primers (Eurogentec, Liège, Belgium) specific to a 16S region (limit of detection 0.1  
310 pg·µl<sup>-1</sup>). *Bacteroides* species DNA were quantified using a commercial double-dye  
311 probe/primer kit using 5 µl<sup>-1</sup> of DNA template following manufacturer's instructions (Path-  
312 *Bacteroides*-spp, Genesig, Primerdesign Ltd, Chandler's Ford, UK). Where *Bacteroides*  
313 concentrations were < 0.2 copy·µl<sup>-1</sup> (i.e. less than 1 copy of DNA in 5 µl<sup>-1</sup> DNA template), these  
314 were considered as artefact and subsequently reported as zero. Negative controls (PCR grade  
315 water) for the entire extraction process were below the limit of detection for both measures.  
316 Ratio data are presented as *Bacteroides*/total bacterial DNA (*Bact./16S*). The intra-assay  
317 coefficients of variation were 6.4% (total 16S) and 24.5% (*Bacteroides*).

318 All statistical analyses were performed using Prism Graphpad software (Prism V.8, La  
319 Jolla, California, USA). Comparisons were made after first establishing normal distribution  
320 using a Shapiro-Wilk test and sphericity using Mauchly's Test. A two-way analysis of variance  
321 (ANOVA) with repeated measures (time x trial) was used to identify differences over time. For  
322 aspherical data, Greenhouse-Geiser corrections were applied for  $\epsilon < 0.75$ , whilst the  
323 Huynh-Feldt correction was applied for  $\epsilon > 0.75$ . Where significant interaction effects  
324 were identified, post-hoc Holm-Bonferroni corrected t-tests were used to determine the  
325 location of variance. When there was only a single comparison (lactulose/rhamnose), a paired  
326 t-test was used to determine between-trial differences. Statistical significance was accepted  
327 at the alpha level of  $p \leq 0.05$ . Effect sizes were calculated based on Cohens D with Hedges  
328 small sample size correction (hedges  $g$ ), with the magnitude of effect classified as small ( $d =$   
329  $0.2$ ), medium ( $d = 0.5$ ) and large ( $d = 0.8$ ) based on standard criteria (Lakens, 2013). Data are  
330 presented as mean  $\pm$  standard deviation (SD). Gastrointestinal symptom severity is presented  
331 as accumulated mean  $\pm$  range of reported symptoms  $\geq 1$  (Gaskell et al., 2019).

332 A sample size estimation was calculated *a priori* using specialist statistical power  
333 software (G\*Power 3.1, Kiel, Germany). Anticipated effect size was derived from a previous  
334 study comparing the influence of acute glutamine ( $0.9 \text{ g}\cdot\text{kg}\cdot\text{FFM}^{-1}$ ) on small intestinal  
335 permeability responses (Zuhl et al., 2015) following exertional-heat stress. In total,  $\geq 6$   
336 participants were considered necessary to detect a significant interaction effect using a two-  
337 way ANOVA with standard alpha (0.05) and beta (0.8) values.

338

339 **RESULTS**

340 Basal urine osmolality (glutamine:  $383 \pm 256$  mOsmol $\cdot$ kg $^{-1}$ ; placebo:  $336 \pm 217$   
341 mOsmol $\cdot$ kg $^{-1}$ ;  $p = 0.57$ ), urine specific gravity (glutamine:  $1.010 \pm 0.008$  AU; placebo:  $1.009 \pm$   
342  $0.006$  AU;  $p = 0.53$ ) and plasma osmolality (glutamine:  $299 \pm 3$  mOsmol $\cdot$ kg $^{-1}$ ; placebo:  $298 \pm 3$   
343 mOsmol $\cdot$ kg $^{-1}$ ;  $p = 0.15$ ) were similar between conditions. The  $\Delta$  plasma volume following the  
344 EHST was comparable in both the glutamine ( $-3.26 \pm 1.81\%$ ) and placebo ( $-3.46 \pm 1.59\%$ ) trials  
345 ( $p = 0.62$ ).

346 Small intestinal permeability (lactulose/rhamnose ratio) was not different between  
347 the glutamine ( $0.030 \pm 0.012$ ) and placebo ( $0.023 \pm 0.006$ ) trials ( $p = 0.06$ ; Figure 2A), though  
348 with a medium effect size favouring placebo supplementation ( $g = 0.73$ ). I-FABP  
349 concentration increased from pre (glutamine:  $2.16 \pm 0.98$  ng $\cdot$ ml $^{-1}$ ; placebo:  $2.60 \pm 1.04$  ng $\cdot$ ml $^{-1}$   
350  $^1$ ) to post-EHST (glutamine:  $4.70 \pm 1.31$  ng $\cdot$ ml $^{-1}$ ; placebo:  $3.98 \pm 1.70$  ng $\cdot$ ml $^{-1}$ ) in both trials  
351 (time;  $p < 0.01$ ). There was an overall time x trial interaction effect ( $p = 0.03$ ) for I-FABP (Figure  
352 2B), however, after post hoc correction this effect was not significant either pre- or post-EHST  
353 ( $p > 0.05$ ). There was a small effect size for post-EHST I-FABP concentration favouring placebo  
354 supplementation ( $g = 0.47$ ). No trial order effects were identified ( $p > 0.05$ ).

355 [Figure 2 – Insert Here]

356 Total 16S DNA was unchanged from pre- (glutamine =  $6.08 \pm 0.98$   $\mu$ g $\cdot$ ml $^{-1}$ ; placebo =  
357  $6.55 \pm 1.75$  pg $\cdot$  $\mu$ l $^{-1}$ ) to post-EHST (glutamine =  $5.97 \pm 0.98$  pg $\cdot$ ml $^{-1}$ ; placebo =  $6.87 \pm 0.91$   
358 pg $\cdot$ ml $^{-1}$ ) in either trial (Figure 2C; time x trial interaction;  $p = 0.49$ ). The effect size for post-  
359 EHST total 16S DNA was large ( $g = 0.95$ ) in favour of the glutamine trial. *Bacteroides*/total 16S  
360 DNA ratio increased (time;  $p = 0.04$ ) from pre (glutamine =  $0.05 \pm 0.05$ ; placebo =  $0.09 \pm 0.08$ )

361 to post-EHST (glutamine =  $0.12 \pm 0.11$ ; placebo =  $0.26 \pm 0.41$ ) in both trials (Figure 2D; time x  
362 trial interaction;  $p = 0.21$ ). The effect size for post-EHST total 16S DNA was small ( $d = 0.60$ ) in  
363 favour of the glutamine trial. In 11/40 samples, *Bacteroides* concentrations were below the  
364 analytical limit of detection ( $0.2 \text{ copy} \cdot \mu\text{l}^{-1}$ ) suggestive of no *Bacteroides* DNA present in the  
365 sample (ratio data presented as zero). No trial order effects were identified ( $p > 0.05$ ).

366 There was no difference in  $T_{\text{core}}$  (Figure 3A; time x trial;  $p = 0.98$ ), mean  $T_{\text{skin}}$  (Figure  
367 3B; time x trial;  $p = 0.49$ ) or  $T_{\text{body}}$  (Figure 3C; time x trial;  $p = 0.93$ ) between the glutamine and  
368 placebo trials. Peak  $T_{\text{core}}$  was  $38.6 \pm 0.4^\circ\text{C}$  in the glutamine trial and  $38.6 \pm 0.5^\circ\text{C}$  in the placebo  
369 trial, respectively ( $p > 0.05$ ). Mean whole body sweat (glutamine:  $1.8 \pm 0.3 \text{ l} \cdot \text{h}^{-1}$ ; placebo:  $1.8$   
370  $\pm 0.3 \text{ l} \cdot \text{h}^{-1}$ ;  $p = 0.43$ ) and % body mass loss (glutamine:  $2.0 \pm 0.3\%$ ; placebo:  $2.0 \pm 0.5\%$ ;  $p =$   
371  $0.48$ ) were similar between conditions. Heart rate increased to a similar extent throughout  
372 the EHST between the two trials (Figure 3D; time x trial;  $p = 0.96$ ). Peak heart rate was  $161 \pm$   
373  $13 \text{ b} \cdot \text{min}^{-1}$  in the glutamine and  $161 \pm 19 \text{ b} \cdot \text{min}^{-1}$  in the placebo trial, respectively.

374 [Figure 3 – Insert Here]

375 RPE (Figure 3E; time x trial;  $p = 0.59$ ) and thermal sensation (Figure 3F; time x trial;  $p$   
376  $= 0.70$ ) increased to a similar extent throughout the EHST between the two trials (Figure 3E;  
377 time x trial;  $p = 0.59$ ). There were no reports (e.g. all 0 scores) of gut discomfort, nausea, total-  
378 , upper- or lower- gastrointestinal symptoms for any participant during either the glutamine  
379 or placebo trial.

380

381 **DISCUSSION**

382           The aim of this study was to determine the influence of low-dose (0.3 g·kg·FFM<sup>-1</sup>)  
383 acute oral glutamine supplementation on small intestinal permeability, epithelial injury and  
384 bacterial translocation biomarkers in response to exertional-heat stress. The main findings  
385 were that low-dose acute oral glutamine supplementation 1-hour before an EHST did not  
386 influence small intestinal permeability (serum lactulose/rhamnose) or epithelial injury  
387 (plasma I-FABP) in comparison to water-alone. Whilst gastrointestinal bacterial translocation  
388 (*Bacteroides*/total 16S DNA) increased following the EHST, this response was also similar  
389 between the glutamine and placebo trials. There was no evidence of subjective  
390 gastrointestinal symptoms in either trial, whilst whole-body physiological (e.g. T<sub>core</sub>, heart  
391 rate) responses were not influenced by supplementation. Together, these data suggest no  
392 benefit of low-dose (0.3 g·kg·FFM<sup>-1</sup>) acute oral glutamine supplementation to support small  
393 intestinal permeability, epithelial injury and bacterial translocation in response to exertional-  
394 heat stress.

395           I-FABP is the prominent biomarker of small intestinal epithelial injury, whereas the  
396 DSAT assesses functional gastrointestinal permeability (Bischoff et al., 2014). In the present  
397 study, overall mean  $\Delta$  I-FABP ( $1.37 \pm 1.101$  ng·ml<sup>-1</sup> [53%]) and absolute DSAT ( $0.023 \pm 0.005$ )  
398 responses were comparable in the placebo trial to what has previously been reported by  
399 our laboratory applying an identical EHST ( $\Delta$  I-FABP = 0.20-1.35 ng·ml<sup>-1</sup> [16-119%]; and DSAT  
400 =  $\sim 0.020$ -0.035) (Ogden et al., 2020b, 2020c). This finding was unanticipated given that  
401 compared to our previous work, rehydration (12 g·kg·BM<sup>-1</sup>) and forearm cold water  
402 immersion (4 minutes in 15°C) practises were intentionally curtailed in attempt to increase  
403 thermoregulatory and cardiovascular strain. However, given that post-EHST hypohydration

404 (~2% vs ~1% body mass loss),  $T_{core}$  (e.g. peak = 38.6 vs. 38.6°C) and heart rate (mean = 145 vs.  
405 150 bpm) were actually similar to our previous studies, the present data are perhaps less  
406 surprising (Chantler et al., 2020). For sake of comparison, in previous research where  
407 permissive dehydration caused an increased in small intestinal epithelial injury (Costa et al.,  
408 2019), these authors were able induce a greater divergence in hydration status between the  
409 euhydrated (~0.5% body mass loss) and hypohydrated conditions (~3% body mass loss).  
410 Overall, the severity of small intestinal epithelial injury and permeability in the present study  
411 is comparable to many previous 60-to-90 minute moderate-intensity (60-70%  $VO_{2max}$ ) EHST  
412 protocols (e.g. Sheahen et al., 2018; Szymanski et al., 2017). It remains to be determined what  
413 intensity, duration and mode of exercise causes the greatest disturbance of the  
414 gastrointestinal barrier when adopting an exercise protocol that controls for either whole-  
415 body physiological strain (e.g. peak  $T_{core}$ ) or total work performed. Indeed, prolonged duration  
416 ( $\geq 2$  hours), moderate-intensity (~60%  $VO_{2max}$ ) exertional-heat stress appears to cause the  
417 greatest increase in plasma I-FABP concentrations (200 – 500% increase; Costa et al., 2020),  
418 however, typically this form of exercise has a lesser influence on GI permeability (e.g. Snipe  
419 et al., 2018; Pugh et al., 2019) in comparison to short duration (< 1 hour), higher-intensity  
420 (~80%  $VO_{2max}$ ) exertional-heat stress (Marchbank et al., 2011; Davison et al., 2016).  
421 Irrespective of the EHST selected, no laboratory study conducted to date has been able to  
422 induce even close-to the severity of small intestinal epithelial injury that was recently  
423 reported in marathon runners incapacitated with suspected heat stroke (~1500% increase;  
424 Walter et al., 2021), thus questioning the clinical relevance of examining gastrointestinal  
425 related risk factors and countermeasures for EHS using sub-clinical laboratory protocols.  
426 Furthermore, whilst not the main objective of this study, Gaskell et al. (2021) recently  
427 questioned the clinical relevance of gastrointestinal integrity loss (I-FABP, bacterial

428 translocation, selected cytokines) on exercise-associated gastrointestinal symptoms,  
429 concluding in a case-series of symptomatic athletes that gastrointestinal integrity responses  
430 are largely normal.

431 Acute high-dose ( $0.9 \text{ g}\cdot\text{kg}\cdot\text{FFM}^{-1}$ ) oral glutamine supplementation has previously been  
432 recommended to protect small intestinal permeability and epithelial injury in response to  
433 exertional-heat stress (Zuhl et al., 2015; Pugh et al., 2017). However, the practicality of this  
434 supplementation regime is questionable, given reports of poor gastrointestinal tolerance (e.g.  
435 nausea, bloating) with this dosage in some individuals in the initial hours following ingestion  
436 (Ward et al., 2003; Ogden et al., 2020d). To overcome this issue, the present study  
437 supplemented participants with a reduced dose of glutamine ( $0.3 \text{ g}\cdot\text{kg}\cdot\text{FFM}^{-1}$ ) 1-hour before  
438 exertional-heat stress, which was found to be universally well tolerated in accordance with  
439 previous studies that supplemented with this dosage (Ziegler et al., 1990; Ogden et al.,  
440 2020d). However, in contrast to the *a priori* hypothesis, low-dose acute oral glutamine  
441 supplementation did not improve either small intestinal epithelial injury or permeability in  
442 response to exertional-heat stress. In fact, small intestinal permeability and epithelial injury  
443 appeared worsened following glutamine supplementation trial with medium and small effect  
444 size, respectively. Specifically, serum lactulose/rhamnose was 30% greater with glutamine  
445 supplementation and peak plasma I-FABP 18% greater with glutamine supplementation.  
446 These outcomes were surprising given that previous literature has consistently demonstrated  
447 acute high-dose ( $0.9 \text{ g}\cdot\text{kg}\cdot\text{FFM}^{-1}$ ) glutamine supplementation blunts  $\Delta$  I-FABP responses by  
448 ~15-25%, and small intestinal permeability responses by 40-50%, when ingested either 1 or 2  
449 hours before exertional-heat stress (Zuhl et al., 2015; Pugh et al., 2017; Osborne et al., 2019).  
450 Whilst Pugh et al. (2017) previously suggested that the benefits of acute oral glutamine

451 supplementation on small intestinal permeability and epithelial injury might be dose-  
452 dependent in response to exertional-heat stress, the present finding is the first to report a  
453 potential adverse effect of acute glutamine supplementation regime on the gastrointestinal  
454 barrier in response to exertional-heat stress. Indeed, the effect sizes reported by Pugh et al.  
455 (2017) that favour acute low-dose glutamine supplementation on small intestinal  
456 permeability (0.25 g·kg·FFM<sup>-1</sup> dose,  $d = 0.60$ ; 0.5 g·kg·FFM<sup>-1</sup> dose  $d = 0.50$ ) and epithelial injury  
457 (0.25 g·kg·FFM<sup>-1</sup> dose,  $d = 0.02$ ; 0.5 g·kg·FFM<sup>-1</sup> dose,  $d = 0.46$ ) in response to exertional-heat  
458 stress, are smaller in magnitude than those reported in the present study for small intestinal  
459 permeability ( $d = 1.16$ ) and epithelial injury ( $d = 0.42$ ) that conversely favour placebo  
460 supplementation. Overall, it is suggested that acute glutamine supplementation in doses *circa*  
461 0.25 – 0.5 g·kg·FFM<sup>-1</sup> has little influence on small intestinal permeability and epithelial injury  
462 in response to exertional-heat stress. Where glutamine has been supplemented in larger  
463 doses *circa* 0.9 g·kg·FFM<sup>-1</sup>, both Pugh et al. (2017;  $d = 0.9$ ) and Zuhl et al. (2015;  $d = 2.0$ ) report  
464 strong positive effects.

465 In comparison to previous research reporting positive results with high-dose oral  
466 glutamine supplementation on small intestinal permeability and epithelial injury , there are  
467 several potential mechanisms that may explain why low-dose glutamine supplementation  
468 offered no protection of the gastrointestinal barrier in the present study. First, the dose  
469 and/or timing of glutamine ingestion might have been insufficient for meaningful induction  
470 of key protective mechanisms. These include: intracellular heat stroke protein (I-HSP)  
471 expression (Singleton and Wischmeyer, 2006); epithelial cell proliferation (Rhoads et al.,  
472 1997); glutathione biosynthesis (Harward et al., 1994); and gastrointestinal TJ protein  
473 expression (Li et al., 2004). Whilst these mechanisms could not be examined in the present

474 study due to the infeasibility of collecting intestinal tissue, previous *in vitro* studies using  
475 intestinal epithelial cells have shown dose-dependent benefits of glutamine supplementation  
476 on these mechanisms inside 1-hour (Wischmeyer et al., 1997). Second, implementation of the  
477 serum lactulose/rhamnose dual-sugar absorption test at a single timepoint following probe  
478 ingestion is potentially confounded by the influence of prior glutamine ingestion on gastric  
479 emptying rate (Du et al., 2018). Whilst this effect is theoretically controlled through  
480 paracellular/transcellular molecular probe ratio correction in 5-hour urine samples  
481 (Bjarnason et al., 1995), the time-courses of absorption of low/high molecular weight probes  
482 in the blood is not necessarily identical (Sequeira et al., 2014). Third, previous studies  
483 conducted trials following an overnight fast, where the placebo supplement was non-caloric  
484 (Zuhl et al., 2015, Pugh et al., 2017). Given regular macronutrient ingestion improves  
485 intestinal vascular perfusion during exertional-heat stress (Snipe et al., 2017), previous  
486 favourable responses with glutamine supplementation might simply be attributable to the  
487 dose-dependent effects with higher energy provision *per se*. Finally, acute glutamine (1 ml of  
488 2% solution) increased mortality when injected into the duodenum of mice at the onset of  
489 75-minute controlled ischemia-reperfusion injury (Omata et al., 2007). In this study, the  
490 adverse effects reported with glutamine supplementation were hypothesised to be attributed  
491 to an enhanced priming of circulating myeloid cells (CD11b expression) and spontaneous  
492 production of reactive oxygen species production. These responses could provide a potential  
493 mechanism for glutamine worsening small intestinal permeability and epithelial injury.

494 Bacterial DNA is an emerging biomarker to assess gastrointestinal bacterial  
495 translocation through high-sensitivity conserved 16S gene sequencing (Paisse et al., 2016).  
496 Compared with traditional bacterial translocation biomarkers (e.g. endotoxin), bacterial DNA

497 assessment is less susceptible to analytical issues surrounding both: (1) exogenous  
498 contamination, given the ability to target phyla/species with high gastrointestinal specificity  
499 (e.g. *Bacteroides*); and (2) liability to hepatic clearance, given that concentrations are largely  
500 similar between portal and systemic blood (Mortensen et al., 2013). Furthermore, to reduce  
501 the influence of potential covariates on *Bacteroides* DNA concentrations, such as the efficacy  
502 of DNA extraction, DNase concentrations, immune function and sample contamination,  
503 correction for total 16S DNA has previously been recommended (March et al., 2019). In the  
504 present study, mean *Bacteroides*/total 16S DNA concentrations increased by  $89 \pm 217\%$   
505 following the EHST in the placebo trial. Previous evidence has reported comparable basal  
506 *Bacteroides*/total 16S DNA ratios ( $\sim 0 - 1.0$ ), though large inter-individual variability in  
507 responses were evident (March et al., 2019; Ogden et al., 2020b, 2020c). For example, in a  
508 previous report from our laboratory, *Bacteroides*/total 16s DNA ratio increased by  $183 \pm 336\%$   
509 in participants with low aerobic fitness ( $VO_{2max} < 50 \text{ ml}\cdot\text{kg}\cdot\text{min}^{-1}$ ), but was unchanged ( $-6 \pm$   
510  $45\%$ ) in participants with high aerobic fitness ( $VO_{2max} > 60 \text{ ml}\cdot\text{kg}\cdot\text{min}^{-1}$ ) following a similar  
511 EHST to that applied in the present study (Ogden et al., 2020c). Thus, gastrointestinal bacterial  
512 translocation assessed using the *Bacteroides*/total 16s DNA ratio, is elevated following brief  
513 subclinical exertional-heat stress in most individuals. The standalone measurement of plasma  
514 total 16S DNA was unchanged in response to exertional-heat stress in the current study,  
515 which is concordant with previous research from our laboratory using a similar EHST (Ogden  
516 et al., 2020b, 2020c).

517         Whilst several studies have previously demonstrated acute oral glutamine  
518 supplementation can support small intestinal permeability and epithelial injury in response  
519 to exertional-heat stress, few studies have assessed whether these benefits translate into

520 reduced downstream gastrointestinal bacterial translocation. In addressing this gap in the  
521 literature, the present study reported no difference in gastrointestinal bacterial translocation  
522 measured using both total 16S DNA and *Bacteroides*/total 16S DNA between the glutamine  
523 and placebo trials following exertional-heat stress. This null effect of glutamine  
524 supplementation on gastrointestinal bacterial translocation was perhaps not surprising given  
525 that glutamine did not simultaneously protect either small intestinal epithelial injury or  
526 permeability. Alternatively, there is some rationale that glutamine supplementation might  
527 have improved microbial neutralisation capacity independent of translocation, which might  
528 explain the observed large effect size for glutamine in blunting total 16S DNA concentrations  
529 following exertional-heat stress. For example, in experimental rodent sepsis models,  
530 glutamine supplementation enhanced: lymphocyte function in gut-associate lymphoid tissue  
531 (Manhart et al., 2001); luminal immunoglobulin concentrations (Fan et al., 2018); and hepatic  
532 integrity upon pathological insult (Cruzat et al., 2014). Of the previous studies assessing the  
533 influence of glutamine supplementation on small intestinal permeability and epithelial injury  
534 around exertional-heat stress, only Zuhl et al. (2015) attempted to monitor gastrointestinal  
535 bacterial translocation through assessment of plasma endotoxin concentration.  
536 Unfortunately, endotoxin concentrations were unchanged following exertional-heat stress in  
537 this study, thus making it unfeasible to assess the efficacy of glutamine supplementation on  
538 gastrointestinal bacterial translocation (Zuhl et al., 2015). Therefore, the present study  
539 provides the first direct evidence that acute-oral glutamine supplementation does not reduce  
540 gastrointestinal bacterial translocation in response to exertional-heat stress.

541           Despite administering a tightly controlled methodological design, the present results  
542 were not without limitations. First, the EHST only evoked moderate disturbance of small

543 intestinal permeability, epithelial injury and bacterial translocation. A previous systematic  
544 review outlined an exercise induced  $T_{core}$  threshold of 38.6°C for gastrointestinal barrier  
545 integrity loss (lactulose/rhamnose, I-FABP and endotoxin) to be commonplace (>50%  
546 incidence) and of 39.0°C for gastrointestinal barrier integrity loss to be universal (100%  
547 incidence; Pires et al., 2017). In this study, participants only exceeded the 38.6°C threshold in  
548 11/20 trials, whilst only 3/20 exceeded the 39.0°C threshold. Notwithstanding this limitation,  
549 the present EHST was chosen as it has robust ecological validity in representing group-based  
550 military work-rest guidance (Spitz et al., 2012) and previously was severe enough to induce  
551 gastrointestinal bacterial translocation (Ogden et al., 2020c). It is recommended that future  
552 research should examine the efficacy of nutritional countermeasures on gastrointestinal  
553 barrier biomarkers during physically arduous field activities (e.g. military selection tests,  
554 wildland firefighting) where participants are exposed to a greater severity of heat strain than  
555 is achievable in the laboratory. Second, *Bacteroides* DNA had poor analytical reliability (mean  
556 duplicate CV = 24.5%), which resulted from a large proportion of samples being close to the  
557 assays minimum level of detection. Future analysis should consider assessment of whole-  
558 blood samples, given that bacterial 16S DNA concentrations in the buffy coat far exceed that  
559 of plasma (Paisse et al., 2016). Third, a standardised diet was not prescribed in the days prior  
560 to experimental trials to minimise participant burden. The full impact of this lack of dietary  
561 standardisation is unclear, though previous studies report little effect of manipulating either  
562 short-term dietary gluten (Lis et al., 2015), carbohydrate (Moncada-Jimenez et al., 2009) or  
563 fermentable oligo- di- mono- saccharide and polyol (FODMAP; Gaskell et al., 2021a)  
564 availability on small intestinal permeability, epithelial injury or bacterial translocation  
565 biomarkers in response to fasted exercise. Finally, implementation of an isocaloric placebo or  
566 standardised pre-trial breakfast would have reduced concerns regarding the extraneous

567 influence of macronutrient provision on examined biomarkers. The decision to utilise a non-  
568 calorific placebo was selected to ensure consistency with previous research (Zuhl et al., 2014,  
569 2015; Pugh et al., 2017; Osborne et al., 2019). It is recommended that future studies look to  
570 examine the efficacy of high-dose glutamine supplementation alongside standardised dietary  
571 guidance for athletic populations.

572         This study assessed the influence of low-dose ( $0.3 \text{ g}\cdot\text{kg}\cdot\text{FFM}^{-1}$ ) acute oral glutamine  
573 supplementation on small intestinal permeability, epithelial injury and bacterial translocation  
574 biomarkers in response to subclinical exertional-heat stress. The glutamine bolus was well-  
575 tolerated, with no adverse gastrointestinal symptoms responses reported for any participant.  
576 Neither small intestinal permeability (serum lactulose/rhamnose) or epithelial injury (plasma  
577 I-FABP) were improved with glutamine supplementation in response to subclinical exertional-  
578 heat stress. In fact, large- and small- effects were observed that showed glutamine worsened  
579 small intestinal permeability and epithelial injury in comparison to placebo supplementation.  
580 Therefore, unlike previous research on this topic supplementing with high-dose ( $0.9 \text{ g}\cdot\text{kg}\cdot\text{FFM}^{-1}$   
581 <sup>1</sup>) acute oral glutamine, these findings show that when supplemented in lower doses,  
582 glutamine has no protective benefit on small intestinal permeability and epithelial injury  
583 during subclinical exertional-heat stress. Downstream gastrointestinal bacterial translocation  
584 assessed via *Bacteroides*/total 16S DNA responses increased following the EHST, however,  
585 there was no clear impact of glutamine supplementation. Given this response, it is  
586 speculatively recommended that the meaningfulness of heightened gastrointestinal barrier  
587 disturbance following glutamine supplementation would not translate into an increased risk  
588 of clinical complications during more severe exertional-heat stress (e.g. exertional-heat  
589 stroke). The peak thermoregulatory strain induced in the present study was sub-clinical (e.g.

590 peak  $T_{\text{core}} = 38\text{-}39.5^{\circ}\text{C}$ ), whereby it is recommended that future research should examine the  
591 efficacy of nutritional countermeasures in more physically demanding field-based  
592 circumstances. These findings do not support the use of acute low-dose oral glutamine  
593 supplementation to protect small intestinal permeability, epithelial injury and prevent  
594 bacterial translocation in response to subclinical exertional-heat stress.

595

596 **REFERENCES**

597 Barnett, A. and Maughan, R.J. (1993). Response of unacclimatized males to repeated weekly  
598 bouts of exercise in the heat. *Br J Sports Med*, 27(1), pp.39-44.

599 Bischoff, S.C., Barbara, G., Buurman, W., Ockhuizen, T., Schulzke, J.D., Serino, M., Tilg, H.,  
600 Watson, A. and Wells, J.M. (2014). Intestinal permeability—a new target for disease  
601 prevention and therapy. *BMC Gastroenterology*, 14(1), pp.189.

602 Bjarnason, I., Macpherson, A. and Hollander, D. (1995). Intestinal permeability: an  
603 overview. *Gastroenterology*, 108(5), pp.1566-1581.

604 Borg, G. (1970). Perceived exertion as an indicator of somatic stress. *Scand J Rehab Med*, 2,  
605 pp.92-98.

606 Cani, P.D. (2018). Human gut microbiome: hopes, threats and promises. *Gut*, 67(9), pp.1716-  
607 1725.

608 Chantler, S., Griffiths, A., Matu, J., Davison, G., Jones, B. and Deighton, K. (2020). The effects  
609 of exercise on indirect markers of gut damage and permeability: A systematic review and  
610 meta-analysis. *Sports Med*, pp.1-12.

611 Costa, R.J., Camões-Costa, V., Snipe, R.M., Dixon, D., Russo, I. and Huschtscha, Z. (2019).  
612 Impact of exercise-induced hypohydration on gastrointestinal integrity, function, symptoms,  
613 and systemic endotoxin and inflammatory profile. *J Appl Physiol*, 126(5), pp.1281-1291.

614 Costa, R.J., Gaskell, S.K., McCubbin, A.J. and Snipe, R.M. (2020). Exertional-heat stress-  
615 associated gastrointestinal perturbations during Olympic sports: Management strategies for  
616 athletes preparing and competing in the 2020 Tokyo Olympic Games. *Temperature*, 7(1),  
617 pp.58-88.

618 Cruzat, V.F., Bittencourt, A., Scomazzon, S.P., Leite, J.S.M., de Bittencourt Jr, P.I.H. and  
619 Tirapegui, J. (2014). Oral free and dipeptide forms of glutamine supplementation attenuate  
620 oxidative stress and inflammation induced by endotoxemia. *Nutrition*, 30(5), pp.602-611.

621 Davison, G., Marchbank, T., March, D.S., Thatcher, R. and Playford, R.J. (2016). Zinc  
622 carnosine works with bovine colostrum in truncating heavy exercise–induced increase in gut  
623 permeability in healthy volunteers. *Am J Clin Nutr*, 104(2), pp.526-536.

624 Demartini, J.K., Casa, D.J., Stearns, R., Belval, L., Crago, A., Davis, R. and Jardine, J. (2015).  
625 Effectiveness of cold water immersion in the treatment of exertional heat stroke at the  
626 Falmouth Road Race. *Med Sci Sports Exer*, 47(2), pp.240-245.

627 Dill, D.B. and Costill, D.L. (1974). Calculation of percentage changes in volumes of blood,  
628 plasma, and red cells in dehydration. *J Appl Physiol*, 37(2), pp.247-248.

629 Du, Y.T., Piscitelli, D., Ahmad, S., Trahair, L.G., Greenfield, J.R., Samocha-Bonet, D., Rayner,  
630 C.K., Horowitz, M. and Jones, K.L. (2018). Effects of Glutamine on Gastric Emptying of Low-  
631 and High-Nutrient Drinks in Healthy Young Subjects—Impact on Glycaemia. *Nutrients*, 10(6),  
632 p.739.

633 Durnin, J.V. and Womersley, J.V. (1974). Body fat assessed from total body density and its  
634 estimation from skinfold thickness: measurements on 481 men and women aged from 16 to  
635 72 years. *Br J Nutr*, 32(1), pp.77-97.

636 Edinburgh, R.M., Hengist, A., Smith, H.A., Travers, R.L., Koumanov, F., Betts, J.A., Thompson,  
637 D., Walhin, J.P., Wallis, G.A., Hamilton, D.L. and Stevenson, E.J. (2018). Preexercise breakfast  
638 ingestion versus extended overnight fasting increases postprandial glucose flux after  
639 exercise in healthy men. *Am J Physiol-Endocrinol Metab*, 315(5), pp.1062-1074.

640 Fallowfield, J.L., Delves, S.K., Hill, N.E., Lanham-New, S.A., Shaw, A.M., Brown, P.E., Bentley,  
641 C., Wilson, D.R. and Allsopp, A.J. (2019). Serum 25-hydroxyvitamin D fluctuations in military  
642 personnel during 6-month summer operational deployments in Afghanistan. *Br J*  
643 *Nutr*, 121(4), pp.384-392.

644 Fan, J., Wu, J., Wu, L.D., Cheng, B., Tao, S.Y., Wang, W., Chen, X., Zeng, P., Wang, Y.B. and  
645 Meng, Q.Y. (2018). Effect of parenteral glutamine supplementation combined with enteral

646 nutrition on Hsp90 expression and Peyer's patch apoptosis in severely burned  
647 rats. *Nutrition*, 47, pp.97-103.

648 Fleming, S.C., Duncan, A., Russell, R.I. and Laker, M.F. (1996). Measurement of sugar probes  
649 in serum: an alternative to urine measurement in intestinal permeability testing. *Clin*  
650 *Chem*, 42(3), pp.445-448.

651 Flood, T.R., Montanari, S., Wicks, M., Blanchard, J., Sharp, H., Taylor, L., Kuennen, M.R. and  
652 Lee, B.J., 2020. Addition of pectin-alginate to a carbohydrate beverage does not maintain  
653 gastrointestinal barrier function during exercise in hot-humid conditions better than  
654 carbohydrate ingestion alone. *Appl Physiol Nutr Metab*, 45(10), pp.1145-1155.

655 Fung, A.A., Zhou, A., Vanos, J.K. and Schmid-Schönbein, G.W. (2021). Enhanced intestinal  
656 permeability and intestinal co-morbidities in heat strain: A review and case for  
657 autodigestion. *Temperature*, pp.1-22.

658 Gaskell, S.K., Snipe, R.M. and Costa, R.J. (2019). Test–Retest Reliability of a Modified Visual  
659 Analog Scale Assessment Tool for Determining Incidence and Severity of Gastrointestinal  
660 Symptoms in Response to Exercise Stress. *Int J Sport Nutr Exer Metab*, 29(4), pp.411-419.

661 Gaskell, S.K., Taylor, B., Muir, J. and Costa, R.J. (2020a). Impact of 24-h high and low  
662 fermentable oligo-, di-, monosaccharide, and polyol diets on markers of exercise-induced  
663 gastrointestinal syndrome in response to exertional heat stress. *Appl Physiol Nutr*  
664 *Metab*, 45(6), pp.569-580.

665 Gaskell, S.K., Rauch, C.E., Parr, A. and Costa, R.J. (2020b). Diurnal versus Nocturnal Exercise-  
666 Impact on the Gastrointestinal Tract. *Med Sci Sport Exer*.

667 Gaskell, S.K., Rauch, C.E. and Costa, R.J. (2021). Gastrointestinal assessment and therapeutic  
668 intervention for the management of exercise-associated gastrointestinal symptoms: A case  
669 series translational and professional practice approach. *Front Physiol*, 12.

670 Gleeson, M. (2008). Dosing and efficacy of glutamine supplementation in human exercise  
671 and sport training. *J Nutr*, 138(10), pp.2045-2049.

672 Harward, T.R., Coe, D., Souba, W.W., Klingman, N. and Seeger, J.M. (1994). Glutamine  
673 preserves gut glutathione levels during intestinal ischemia/reperfusion. *J Surg Res*, 56(4),  
674 pp.351-355.

675 Hond, E.D. (1999). Effect of glutamine on the intestinal permeability changes induced by  
676 indomethacin in humans. *Aliment Pharmacol Ther*, 13(5), pp.679-685.

677 Jay, O. and Kenny, G.P. (2007). The determination of changes in body heat content during  
678 exercise using calorimetry and thermometry. *J Human-Environ System*, 10(1), pp.19-29.

679 Jonvik, K.L., Lenaerts, K., Smeets, J.S., Kolkman, J.J., Van Loon, L.J. and Verdijk, L.B. (2019).  
680 Sucrose but not nitrate ingestion reduces strenuous cycling-induced intestinal injury. *Med*  
681 *Sci Sport Exer*, pp.436-444.

682 Lacey, J.M. and Wilmore, D.W. (1990). Is glutamine a conditionally essential amino  
683 acid?. *Nutr Rev*, 48(8), pp.297-309.

684 Lakens, D. (2013). Calculating and reporting effect sizes to facilitate cumulative science: a  
685 practical primer for t-tests and ANOVAs. *Front Psych*, 4, p.863.

686 Lambert, G.P., Broussard, L.J., Mason, B.L., Mauermann, W.J. and Gisolfi, C.V., 2001.  
687 Gastrointestinal permeability during exercise: effects of aspirin and energy-containing  
688 beverages. *J Appl Physiol*, 90(6), pp.2075-2080.

689 Leon, L.R. and Bouchama, A. (2011). Heat stroke. *Compr Physiol*, 5(2), pp.611-647.

690 Li, N., Lewis, P., Samuelson, D., Liboni, K. and Neu, J. (2004). Glutamine regulates Caco-2 cell  
691 tight junction proteins. *Am J Physiol-Gastrointest Liver Physiol*, 287(3), pp.726-733.

692 Lim, C. (2018). Heat sepsis precedes heat toxicity in the pathophysiology of heat stroke—a  
693 new paradigm on an ancient disease. *Antioxidants*, 7(11), p.149.

694 Lis, D., Stellingwerff, T., Kitic, C.K., Ahuja, K.D. and Fell, J. (2015). No effects of a short-term  
695 gluten-free diet on performance in nonceliac athletes. *Med Sci Sport Exer*, 47(12), pp.2563-  
696 2570.

697 Manhart, N., Vierlinger, K., Spittler, A., Bergmeister, H., Sautner, T. and Roth, E. (2001). Oral  
698 feeding with glutamine prevents lymphocyte and glutathione depletion of Peyer's patches in  
699 endotoxemic mice. *Ann Surg*, 234(1), p.92.

700 March, D.S., Jones, A.W., Thatcher, R. and Davison, G. (2019). The effect of bovine  
701 colostrum supplementation on intestinal injury and circulating intestinal bacterial DNA  
702 following exercise in the heat. *Eur J Nutri*, 58(4), pp.1441-1451.

703 Marchbank, T., Davison, G., Oakes, J.R., Ghatei, M.A., Patterson, M., Moyer, M.P. and  
704 Playford, R.J. (2011). The nutraceutical bovine colostrum truncates the increase in gut  
705 permeability caused by heavy exercise in athletes. *Am J Physiol-Gastrointest Liver*  
706 *Physiol*, 300(3), pp.477-484.

707 Met Office. (2019). Cambourne. [Online]. Available at:  
708 [https://www.metoffice.gov.uk/pub/data/weather/uk/climate/stationdata/cambornedata.tx](https://www.metoffice.gov.uk/pub/data/weather/uk/climate/stationdata/cambornedata.txt)  
709 [t](https://www.metoffice.gov.uk/pub/data/weather/uk/climate/stationdata/cambornedata.txt) [Accessed 23/02/2020]

710 Moncada-Jiménez, J., Plaisance, E.P., Araya-Ramírez, F., Taylor, J.K., Ratcliff, L., Mestek, M.L.,  
711 Grandjean, P.W. and AragonVargas, L.F. (2010). Acute hepatic response to diet modification  
712 and exercise-induced endotoxemia during a laboratory-based duathlon. *Biol Sport*, 27(2),  
713 111-117.

714 Mortensen, C., Karlsen, S., Grønbæk, H., Nielsen, D.T., Frevert, S., Clemmesen, J.O., Møller,  
715 S., Jensen, J.S. and Bendtsen, F. (2013). No difference in portal and hepatic venous bacterial  
716 DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt  
717 insertion. *Liver Int*, 33(9), pp.1309-1315.

718 Newsholme, P., Procopio, J., Lima, M.M.R., Pithon-Curi, T.C. and Curi, R. (2003). Glutamine  
719 and glutamate—their central role in cell metabolism and function. *Cell Biochem*  
720 *Funct*, 21(1), pp.1-9.

721 Ogden, H.B., Child, R.B., Fallowfield, J.L., Delves, S.K., Westwood, C.S. and Layden, J.D.  
722 (2020a). The Gastrointestinal Exertional Heat Stroke Paradigm: Pathophysiology,  
723 Assessment, Severity, Aetiology and Nutritional Countermeasures. *Nutrients*, 12, 537.

724 Ogden, H.B., Child, R.B., Fallowfield, J.L., Delves, S.K., Westwood, C.S., Millyard, A. and  
725 Layden, J.D. (2020d). Gastrointestinal Tolerance of Low, Medium and High Dose Acute Oral  
726 l-Glutamine Supplementation in Healthy Adults: A Pilot Study. *Nutrients*, 12(10), pp.2953.

727 Ogden, H.B., Fallowfield, J.L., Child, R.B., Davison, G., Fleming, S.C, Edinburgh, R.M., Delves,  
728 S.K., Millyard, A., Westwood, C.S. and Layden, J. (2020b). Reliability of gastrointestinal  
729 barrier integrity and microbial translocation biomarkers at rest and following exertional heat  
730 stress. *Physiol Rep*, 8, e14374.

731 Ogden, H.B., Fallowfield, J.L., Child, R.B., Davison, G., Fleming, S.C, Delves, S.K., Millyard, A.,  
732 Westwood, C.S. and Layden, J. (2020c). Influence of Aerobic Fitness on Gastrointestinal  
733 Barrier Integrity and Microbial Translocation Following a Fixed-Intensity Military Exertional  
734 Heat Stress Test. *Eur J Appl Physiol*, 120(10), 2325-2337.

735 Omata, J., Fukatsu, K., Ueno, C., Maeshima, Y., Saitoh, D. and Mochizuki, H. (2007).  
736 Intraluminal glutamine administration during ischemia worsens survival after gut ischemia-  
737 reperfusion. *J Surg Res*, 143(2), pp.260-264.

738 Osborne, J.O., Stewart, I.B., Beagley, K.W., Borg, D.N. and Minett, G.M. (2019). Acute  
739 glutamine supplementation does not improve 20-km self-paced cycling performance in the  
740 heat. *Eur J Appl Physiol*, 119(11-12), pp.2567-2578.

741 Païssé, S., Valle, C., Servant, F., Courtney, M., Burcelin, R., Amar, J. and Lelouvier, B. (2016).  
742 Comprehensive description of blood microbiome from healthy donors assessed by 16 S  
743 targeted metagenomic sequencing. *Transfusion*, 56(5), pp.1138-1147.

744 Pires, W., Veneroso, C.E., Wanner, S.P., Pacheco, D.A., Vaz, G.C., Amorim, F.T., Tonoli, C.,  
745 Soares, D.D. and Coimbra, C.C. (2017). Association between exercise-induced hyperthermia  
746 and intestinal permeability: a systematic review. *Sports Med*, 47(7), pp.1389-1403.

747 Pugh, J.N., Sage, S., Hutson, M., Doran, D.A., Fleming, S.C., Highton, J., Morton, J.P. and  
748 Close, G.L. (2017). Glutamine supplementation reduces markers of intestinal permeability  
749 during running in the heat in a dose-dependent manner. *Eur J Appl Physiol*, 117(12),  
750 pp.2569-2577.

751 Pugh, J.N., Sparks, A.S., Doran, D.A., Fleming, S.C., Langan-Evans, C., Kirk, B., Fearn, R.,  
752 Morton, J.P. and Close, G.L. (2019). Four weeks of probiotic supplementation reduces GI  
753 symptoms during a marathon race. *Eur J Appl Physiol*, 119(7), pp.1491-1501.

754 Ramanathan, N.L. (1964). A new weighting system for mean surface temperature of the  
755 human body. *J Appl Physiol*, 19(3), pp.531-533.

756 Rhoads, J.M., Argenzio, R.A., Chen, W., Rippe, R.A., Westwick, J.K., Cox, A.D., Berschneider,  
757 H.M. and Brenner, D.A. (1997). L-glutamine stimulates intestinal cell proliferation and  
758 activates mitogen-activated protein kinases. *Am J Physiol-Gastrointest Liver Physiol*, 272(5),  
759 pp.943-953.

760 Sessions, J., Bourbeau, K., Rosinski, M., Szczygiel, T., Nelson, R., Sharma, N. and Zuhl, M.,  
761 2016. Carbohydrate gel ingestion during running in the heat on markers of gastrointestinal  
762 distress. *Eur J Sport Sci*, 16(8), pp.1064-1072.

763 Sequeira, I.R., Lentle, R.G., Kruger, M.C. and Hurst, R.D. (2014). Standardising the lactulose  
764 mannitol test of gut permeability to minimise error and promote comparability. *PLoS*  
765 *One*, 9(6).

766 Sheahen, B.L., Fell, J.W., Zadow, E.K., Hartley, T.F. and Kitic, C.M. (2018). Intestinal damage  
767 following short-duration exercise at the same relative intensity is similar in temperate and  
768 hot environments. *Appl Physiol Nutr Metab*, 43(12), pp.1314-1320.

769 Shirreffs, S.M. and Maughan, R.J. (1994). The effect of posture change on blood volume,  
770 serum potassium and whole body electrical impedance. *Eur J Appl Physiol Occ Physiol*, 69(5),  
771 pp.461-463.

772 Singleton, K.D. and Wischmeyer, P.E. (2006). Oral glutamine enhances heat shock protein  
773 expression and improves survival following hyperthermia. *Shock*, 25(3), pp.295-299.

774 Snipe, R.M., Khoo, A., Kitic, C.M., Gibson, P.R. and Costa, R.J. (2017). Carbohydrate and  
775 protein intake during exertional heat stress ameliorates intestinal epithelial injury and small  
776 intestine permeability. *Appl Physiol Nutr Metab*, 42(12), pp.1283-1292.

777 Spitz, M.G., Castellani, J.W., Freund, B.J. and Sawka, M.N. (2012). [Online]. Available at:  
778 <https://apps.dtic.mil/dtic/tr/fulltext/u2/a571324.pdf> [Accessed 30/3/2020].

779 Szymanski, M.C., Gillum, T.L., Gould, L.M., Morin, D.S. and Kuennen, M.R. (2018). Short-term  
780 dietary curcumin supplementation reduces gastrointestinal barrier damage and  
781 physiological strain responses during exertional heat stress. *J Appl Physiol (Bethesda, Md.:  
782 1985)*, 124(2), pp.330-340.

783 Toner, M.M., Drolet, L.L. and Pandolf, K.B. (1986). Perceptual and physiological responses  
784 during exercise in cool and cold water. *Percept Mot Skills*, 62(1), pp.211-220.

785 van Nieuwenhoven, M.A., Brouns, F. and Brummer, R.J.M. (2004). Gastrointestinal profile of  
786 symptomatic athletes at rest and during physical exercise. *Eur J Applied Physiol*, 91(4),  
787 pp.429-434.

788 Wallace, R.F., Kriebel, D., Punnett, L., Wegman, D.H. and Amoroso, P.J. (2007). Prior heat  
789 illness hospitalization and risk of early death. *Environ Res*, 104(2), pp.290-295.

790 Walter, E., Gibson, O.R., Stacey, M., Hill, N., Parsons, I.T. and Woods, D., 2021. Changes in  
791 gastrointestinal cell integrity after marathon running and exercise-associated collapse. *Eur J  
792 Appl Physiol*, 121(4), pp.1179-1187.

793 Ward, E., Picton, S., Reid, U., Thomas, D., Gardener, C., Smith, M., Henderson, M., Holden,  
794 V., Kinsey, S., Lewis, I. and Allgar, V. (2003). Oral glutamine in paediatric oncology patients: a  
795 dose finding study. *Eur J Clin Nutr*, 57(1), pp.31-36.

796 Wischmeyer, P.E., Musch, M.W., Madonna, M.B., Thisted, R. and Chang, E.B. (1997).  
797 Glutamine protects intestinal epithelial cells: role of inducible HSP70. *Am J Physiol-*  
798 *Gastrointest Liver Physiol*, 272(4), pp.879-884.

799 Ziegler, T.R., Benfell, K., Smith, R.J., Young, L.S., Brown, E., Ferrari-Baliviera, E., Lowe, D.K.  
800 and Wilmore, D.W. (1990). Safety and metabolic effects of L-glutamine administration in  
801 humans. *J Parenter Enteral Nutr*, 14, pp.137-146.

802 Zuhl, M., Dokladny, K., Mermier, C., Schneider, S., Salgado, R. and Moseley, P. (2015). The  
803 effects of acute oral glutamine supplementation on exercise-induced gastrointestinal  
804 permeability and heat shock protein expression in peripheral blood mononuclear cells. *Cell*  
805 *Stress Chaperones*, 20(1), pp.85-93.

806 Zuhl, M.N., Lanphere, K.R., Kravitz, L., Mermier, C.M., Schneider, S., Dokladny, K. and  
807 Moseley, P.L. (2014). Effects of oral glutamine supplementation on exercise-induced  
808 gastrointestinal permeability and tight junction protein expression. *J Appl Physiol*, 116(2),  
809 pp.183-191.

810

811

812

813

814

815



817 **Table 1.** Participant demographic characteristics

Measure	Mean ± SD
Age (years)	32 ± 6
Height (m)	1.80 ± 0.07
Body Mass (kg)	83.6 ± 11.6
Physical Activity (h·week <sup>-1</sup> )	6 ± 2
Body Fat (%)	17.0 ± 4.0
$\dot{V}O_{2max}$ (ml·kg <sup>-1</sup> ·min <sup>-1</sup> )	48 ± 5


818

819

820

821


822



823

824 **Figure 1.** Schematic illustration of the experimental measurement timings

825




826

827

828 **Figure 2.** Gastrointestinal biomarker responses to exertional-heat stress: (A) = L/R ratio at 90  
 829 minutes; (B) I-FABP; (C) = total 16S DNA; and (D) *Bacteroides*/total 16S DNA. Overall effect  
 830 of time (\* $p \leq 0.05$ ; \*\*  $p \leq 0.01$ ).

831



832

833 **Figure 3.** Whole-body physiological responses to exertional-heat stress: (A) = core  
 834 temperature; (B) = mean skin temperature; (C) = mean body temperature; (D) = heart rate;  
 835 (E) = thermal sensation; and (F) = rate of perceived exertion. Solid line = glutamine, broken  
 836 line = placebo. Overall effect of time (\* $p \leq 0.05$ ; \*\*  $p \leq 0.01$ ).

837

838

839

840